US-ATG-F
Phase 3Biologic
US-ATG-F is one of 45 biologic programs targeting Chronic Graft Versus Host Disease. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
55 competitors in Chronic Graft Versus Host Disease
#DrugCompanyPhaseTrials
1Cellcept
RocheApproved
Erivedge
RocheApproved
Neoral
NovartisApproved
Olumiant
Eli LillyApproved
Decadron
AAspen Global Incorporated
Approved
Pulmicort
SSalix
Approved
Kyprolis
VVirionyx Corporation Limited
Approved
Cytoxan
BBaxter Healthcare Corporation
Approved
Qvar
SSchering-Plough
Approved
Rayos
RRoxane Laboratories
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for US-ATG-F. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- NNeovii Biotech